Business Description
A Plus Biotechnology Co Ltd
ISIN : TW0006918006
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.59 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | 1.03 | |||||
Interest Coverage | 78.39 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 8.07 | |||||
Beneish M-Score | -3.28 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8.2 | |||||
3-Year EBITDA Growth Rate | -1.8 | |||||
3-Year EPS without NRI Growth Rate | -0.2 | |||||
3-Year FCF Growth Rate | 9.8 | |||||
3-Year Book Growth Rate | 2.4 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 31.24 | |||||
9-Day RSI | 37.42 | |||||
14-Day RSI | 40.36 | |||||
6-1 Month Momentum % | 16.83 | |||||
12-1 Month Momentum % | 83.02 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.85 | |||||
Quick Ratio | 2.61 | |||||
Cash Ratio | 1.71 | |||||
Days Inventory | 484.35 | |||||
Days Sales Outstanding | 74.47 | |||||
Days Payable | 55.44 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 3.38 | |||||
Dividend Payout Ratio | 0.37 | |||||
Forward Dividend Yield % | 3.38 | |||||
5-Year Yield-on-Cost % | 3.37 | |||||
3-Year Average Share Buyback Ratio | -1.8 | |||||
Shareholder Yield % | 4.28 |
Profitability Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 69.98 | |||||
Operating Margin % | 26.86 | |||||
Net Margin % | 7.9 | |||||
FCF Margin % | 25.17 | |||||
ROE % | 6.46 | |||||
ROA % | 4.88 | |||||
ROIC % | 21.21 | |||||
ROC (Joel Greenblatt) % | 13.87 | |||||
ROCE % | 7.79 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 43.52 | |||||
PE Ratio without NRI | 43.43 | |||||
Price-to-Owner-Earnings | 305.73 | |||||
PS Ratio | 3.46 | |||||
PB Ratio | 2.84 | |||||
Price-to-Tangible-Book | 2.98 | |||||
Price-to-Free-Cash-Flow | 13.79 | |||||
Price-to-Operating-Cash-Flow | 13.37 | |||||
EV-to-EBIT | 29.12 | |||||
EV-to-EBITDA | 21.65 | |||||
EV-to-Revenue | 3.11 | |||||
EV-to-FCF | 13.13 | |||||
Price-to-Graham-Number | 2.38 | |||||
Price-to-Net-Current-Asset-Value | 4.51 | |||||
Price-to-Net-Cash | 39.17 | |||||
Earnings Yield (Greenblatt) % | 3.44 | |||||
FCF Yield % | 7.31 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
A Plus Biotechnology Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil NT$) | 713.741 | ||
EPS (TTM) (NT$) | 1.88 | ||
Beta | 0 | ||
Volatility % | 50.87 | ||
14-Day RSI | 40.36 | ||
14-Day ATR (NT$) | 2.335301 | ||
20-Day SMA (NT$) | 83.18 | ||
12-1 Month Momentum % | 83.02 | ||
52-Week Range (NT$) | 43.85 - 96.9 | ||
Shares Outstanding (Mil) | 30.47 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 8 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
A Plus Biotechnology Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
A Plus Biotechnology Co Ltd Stock Events
Event | Date | Price(NT$) | ||
---|---|---|---|---|
No Event Data |
A Plus Biotechnology Co Ltd Frequently Asked Questions
What is A Plus Biotechnology Co Ltd(ROCO:6918)'s stock price today?
When is next earnings date of A Plus Biotechnology Co Ltd(ROCO:6918)?
Does A Plus Biotechnology Co Ltd(ROCO:6918) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |